Brain metastases in malignant pleural mesothelioma

详细信息    查看全文

• 作者：Tomoko Yamagishi ; Nobukazu Fujimoto ; Yosuke Miyamoto…
• 关键词：Asbestos ; Malignant pleural mesothelioma ; Brain metastases ; Central nervous system ; Brain
• 刊名：Clinical & Experimental Metastasis
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：33
• 期：3
• 页码：231-237
• 全文大小：387 KB
• 参考文献：1.Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, Kishimoto T (2012) National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 103:483–490CrossRef PubMed
  2.Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–245CrossRef PubMed
  3.Wen P, Black P, Loeffler J (2001) Metastatic brain cancer. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 2655–2670
  4.Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54CrossRef PubMed
  5.Falconieri G, Grandi G, DiBonito L, Bonifacio-Gori D, Giarelli L (1991) Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature. Arch Pathol Lab Med 115:591–595PubMed
  6.Chari A, Kolias AG, Allinson K, Santarius T (2015) Cerebral metastasis of a malignant pleural mesothelioma: a case report and review of the literature. Cureus 7:e241. doi:10.​7759/​cureus.​241 PubMed
  7.Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRef PubMed
  8.Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23:184–189CrossRef PubMed
  9.Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723–731CrossRef PubMed
  10.Edwards J, Abrams K, Leverment J, Spyt T, Waller D, O’Byrne K (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731–735CrossRef PubMed PubMedCentral
  11.Miller AC, Miettinen M, Schrump DS, Hassan R (2014) Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc 11:1075–1081CrossRef PubMed PubMedCentral
  12.Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR (2010) Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer 116:5038–5046. doi:10.​1002/​cncr.​25254 CrossRef PubMed
  13.Hsiao SH, Chung CL, Chou YT, Lee HL, Lin SE, Liu HE (2013) Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer 82:319–323. doi:10.​1016/​j.​lungcan.​2013.​08.​004 CrossRef PubMed
  14.Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR (2015) Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat 151:225–232. doi:10.​1007/​s10549-015-3381-8 CrossRef PubMed
  15.Frankel TL, Bamboat ZM, Ariyan C, Coit D, Sabel MS, Brady MS (2014) Predicting the development of brain metastases in patients with local/regional melanoma. J Surg Oncol 109:770–774. doi:10.​1002/​jso.​23574 CrossRef PubMed
  16.Mansfield AS, Symanowski JT, Peikert T (2014) Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer 133–136. doi: 10.​1016/​j.​lungcan.​2014.​08.​017
  17.Finn RS, Brims FJ, Gandhi A, Olsen N, Musk AW, Maskell NA, Lee YC (2012) Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients. Chest 142:1267–1273CrossRef PubMed
  18.Ishikawa T, Wanifuchi H, Abe K, Kato K, Watanabe A, Okada Y (2010) Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage. Neurol Med Chir (Tokyo) 50:1027–1030CrossRef
  19.Colleoni M, Liessi G, Avventi C, Pancheri F, Sgarbossa G, Vicario G, Manente P (1996) Response to chemotherapy of brain metastases from malignant pleural mesothelioma. Tumori 82:456–458PubMed
  20.Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA (2013) A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J 41:18–24CrossRef PubMed
  
• 作者单位：Tomoko Yamagishi (1)
  Nobukazu Fujimoto (2)
  Yosuke Miyamoto (1)
  Michiko Asano (1)
  Yasuko Fuchimoto (1)
  Sae Wada (1)
  Kenichi Kitamura (1)
  Shinji Ozaki (1)
  Hideyuki Nishi (3)
  Takumi Kishimoto (4)
  
  1. Department of Respiratory Medicine, Okayama Rosai Hospital, Okayama, Japan
  2. Department of Medical Oncology, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Minamiku, Okayama, 702-8055, Japan
  3. Department of Surgery, Okayama Rosai Hospital, Okayama, Japan
  4. Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan
  
• 刊物主题：Cancer Research; Biomedicine general; Oncology; Hematology; Surgical Oncology;
• 出版者：Springer Netherlands
• ISSN：1573-7276

文摘

The brain is a rare site of metastasis in malignant pleural mesothelioma (MPM), and its clinical features and prognosis remain unclear. The aim of this study was to investigate the incidence, prognosis, and risk factors for brain metastases (BM) in MPM patients. Between July 1993 and October 2014, 150 patients with histologically proven MPM were included in this retrospective study. The cumulative incidence of BM was estimated with the Kaplan–Meier method, and differences between groups were analyzed by the log-rank test. Multivariate logistic regression analysis was applied to assess risk factors for BM. The median follow-up time was 11 months (range 0–154.0 months). A total of eight patients (5.3 %) developed BM during the course of their illness. Multivariate analysis identified age <65 years (odds ratio [OR] = 5.83, p = 0.038) and International Mesothelioma Interest Group stage IV (OR = 1.69, p = 0.040) as independent factors related to increased risk of developing BM. The 1-and 2-year cumulative rates of BM were 4.0 % (95 % confidence intervals [CI] 1.4–8.5 %) and 5.3 % (95 % CI 2.3–10.2 %), respectively. Our study showed that the overall survival (OS) of patients with BM was worse than that of patients without BM (median OS 6.5 vs. 11.0 months, p = 0.037). The prognosis for BM in MPM patients is poor. Clinicians should perform careful screening for BM, especially in patients with risk factors.